# MEXIDOL® in the Rehabilitation Treatment of Patients With Acute Cerebral Failure

> **NCT06221826** · PHASE4 · COMPLETED · sponsor: **Pharmasoft** · enrollment: 60 (actual)

## Conditions studied

- Ischemic Stroke, Acute

## Interventions

- **DRUG:** Mexidol

## Key facts

- **NCT ID:** NCT06221826
- **Lead sponsor:** Pharmasoft
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-17
- **Primary completion:** 2023-09-12
- **Final completion:** 2023-09-12
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06221826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06221826, "MEXIDOL® in the Rehabilitation Treatment of Patients With Acute Cerebral Failure". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT06221826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*